Abstract
Three carboranyltetraphenylporphyrins containing 40 or 80 boron atoms were synthesized and evaluated for their biodistribution and toxicity in EMT-6 tumor-bearing mice. Copper (II) meso-5,10,15,20-tetrakis[3-methoxy-4-( o-carboranylmethoxy)phenyl]porphyrin, 6, and copper (II) meso-5,10,15,20-tetrakis[3-hydroxy-4-( o-carboranylmethoxy)phenyl]porphyrin, 8, are B 40 congeners with different lipophilicities, each less than their B 80 congener, copper (II) meso-5,10,15,20-tetrakis[ m-(3,5-di- o-carboranylmethoxybenzyloxy)phenyl]porphyrin, 18. Two days after the last of a series of ip injections in BALB/c mice bearing EMT-6 mammary tumors, a dose of 185 mg/kg 6 (54 mg/kg B) delivered over 3.5 times the concentration of boron to tumor (169 μg/g B) than did 118 mg/kg 8 (36 mg/kg B), which delivered 35 μg/g B, or 87 mg/kg 18 (30 mg/kg B), which delivered 46 μg/g B. The tumor-to-blood and tumor-to-brain boron concentration ratios at that time for all three porphyrins exceeded 80:1. Two days after the last injection, there resulted moderate thrombocytopenia that essentially disappeared two days later from 6 and 18, and mild leukocytosis from 6, 8, and 18, all of which were clinically inconsequential. Thus, 6 may rank among the most clinically promising carboranyl porphyrins ever made to deliver 10B to tumors for boron neutron-capture therapy (BNCT) that has also been tested for its toxicity in vivo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have